UHT heads into its July 28 earnings print with a notable contrast between a CEO who has repeatedly bought the stock at higher prices and a short position that just jumped sharply in a single session.
The most striking data point in this setup is the insider history. Chairman and CEO Alan Miller has purchased shares on at least five separate occasions since 2022 — most recently in October 2025, when he bought 12,247 shares at roughly $37, a transaction worth around $453,000. The stock now trades at $44.28, up 3.2% over the past month and 1.3% on the week. That pattern of CEO buying at prices well below current levels sets a meaningful confidence signal heading into the print. The only recent insider activity in the other direction was a small Vice President sale of 462 shares in June — negligible in scale by comparison.
Short interest complicates the picture slightly, though not dramatically. Shorts rose nearly 70% in a single day on July 24, lifting the SI % of float to 2.8% — but that jump appears to be a mean reversion. The figure had hovered near 4–6% of float in late June before collapsing through mid-July, making the recent pop look more like a normalisation than a new bearish campaign. Borrow remains extremely cheap at 0.36%, and availability is enormous — over 5,900% of outstanding short interest — meaning there is no friction whatsoever for either side of this trade. The ORTEX short score nudged up to 33.8 on July 24 from a range around 30, but remains well within neutral territory.
Options positioning adds little heat to the debate. The put/call ratio of 0.35 is fractionally below its 20-day average of 0.36, essentially flat and a world away from the defensive spike near 1.6 seen in late June. Earlier in the summer, when UHT's short count was running higher and the borrow market was tighter, options traders were meaningfully more cautious — that anxiety has since drained from the market. Peer healthcare REITs have had a firm week: VTR gained 4.6% and WELL added 3.6%, while UHT's 1.3% gain leaves it lagging the broader sector rally.
The analyst picture is too stale to lean on — the sole coverage comes from Freedom Broker, with the most recent action dating to November 2025, and the consensus mean target of $42 sits below the current price, a discrepancy that likely reflects the stock's rally rather than any fresh bearish conviction. With UHT trading at a premium to that dated target and the CEO having accumulated shares below current levels, the earnings report will test whether the trust's fundamentals — occupancy, lease renewals, and distribution coverage — can justify the price the market has already awarded it.
See the live data behind this article on ORTEX.
Open UHT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
